Nassir Ghaemi

DSM debates - Volume 2 (Psychology Today: Mood Swings, #5) (eBook, ePUB)

• Format: ePub

Produktbeschreibung

Between 2009 and 2013, Nassir Ghaemi debated Allen Frances and other DSM supporters and critics in the Psychology Today blog website. In these debates, it became clear to Ghaemi that the supporters of DSM, like Frances, and the critics of DSM all shared a similar perspective: an anti-scientific attitude steeped in postmodernist cultural assumptions. They criticized DSM for being too medical and too biological whereas the problem with DSM, according to Ghaemi, is that it is not medical, biological, and scientific enough.

In these three volumes of posts and links to other posts among his critics, Ghaemi lays bare what is wrong with DSM and what is wrong with the critics of DSM: the same thing - postmodernist anti-science attitudes.

In this volume, the following chapters are presented:

• What could have been: The costs of DSM-IV "pragmatism"
• The disorder of "disorder"
• DSM and disease
• Imagining a new DSM
• What do we want our diagnoses to do?

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, CY, CZ, D, DK, EW, E, FIN, F, GR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Nassir Ghaemi
• Erscheinungstermin: 28. Oktober 2019
• Englisch
• ISBN-13: 9781393487159
• Artikelnr.: 59221790

Autorenporträt

S. Nassir Ghaemi MD MPH is a psychiatrist and author. He is Professor of Psychiatry at Tufts University and Lecturer on Psychiatry at Harvard Medical School. He has published multiple academic books, including Clinical Psychopharmacology (Oxford University Press, 2019), and is author of A First-Rate Madness: Exploring the LInks between Mental Illness and Leadership (Penguin, 2011), a New York Times bestseller. He has published over 200 scientific articles, over 50 book chapters, and is a peer reviewer for many scientific journals, as well as Associate Editor of Acta Psychiatrica Scandinavica

Disclosure: Since 2017, Dr. Ghaemi also has been employed at Novartis Institutes for Biomedical Research in Cambridge, MA as a director of early drug discovery research in psychiatry. The views expressed here are his alone, and do not necessarily reflect those of any of his employers.